MDNA News and Press, Medicenna Therapeutics Corp. From 12/31/20

Medicenna Therapeutics (MDNA) has entered into a sales agreement with SVB Leerink, pursuant to which the Company may, from time to time sell, through ATM offerings on Nasdaq for an aggregate offering price of up to $25M. The Company plans to use the net proceeds of the ATM Offering, if any, f...

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with SVB Leerin...

Gainers: Tenax Therapeutics (TENX) +100%.Universal Security Instruments (UUU) +96%.Technical Communications (TCCO) +63%.Koss (KOSS) +49%.WISeKey International Holding AG (WKEY) +42%.Oxbridge Re Holdings (OXBR) +34%.Immersion Corporation (IMMR) +33%.Gannett (GCI) +32%.Bionano Genomics (BN...

CNS Pharmaceuticals (CNSP) +62%.Cyclo Therapeutics (CYTH) +47%.Mereo BioPharma Group (MREO) +38% on licensing pact with Ultragenyx.DermTech (DMTK) +23% after announcing topline results from its TRUST Study of the company’s non-invasive melanoma rule-out test, the Pigmented Le...

- Presentation taking place today , December 9 , 2020 at 10:50 AM ET TORONTO and HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology c...

-  Call will take place on Friday, December 11, 2020 at 11:00 AM ET TORONTO and HOUSTON, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, t...

TORONTO and HOUSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will ...

TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will be presenting two on-demand oral presentations as part of the 2020 Socie...

Medicenna Therapeutics (MDNA): FQ2 GAAP EPS of -C$0.08.Cash, cash equivalents and marketable securities of C$34.2M.Press Release For further details see: Medicenna Therapeutics reports Q2 results

TORONTO and HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended Septembe...